Trial Profile

A Phase IV, Randomised Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Meningococcal vaccine group C conjugate (Primary) ; Hib-DTaP-poliovirus vaccine; Hib-meningococcal vaccine group C conjugate; Measles mumps and rubella virus vaccine; Pneumococcal 7-valent CRM197 vaccine conjugate
Indications Diphtheria; Haemophilus infections; Measles; Meningococcal group C infections; Mumps; Pertussis; Pneumococcal infections; Poliomyelitis; Rubella; Tetanus
Focus Pharmacodynamics

10 Feb 2012 Results published in the Pediatric Infectious Disease Journal.
01 Sep 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
01 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com